Nektar Therapeutics 15min chart: RSI overbought, KDJ death cross.

Nektar Therapeutics's 15-minute chart has reached an overbought level as indicated by the RSI, and a death cross in the KDJ has been triggered at 08/13/2025 13:15. This suggests that the stock price has risen too quickly and is no longer supported by fundamentals, leading to a shift in momentum towards the downside and a potential decrease in value.

Nektar Therapeutics (NKTR) reported a significant earnings miss for the second quarter of 2025, with an actual EPS of -$2.78 compared to the forecasted -$0.20. This resulted in a surprising 1,290% deviation from expectations [4]. Despite the substantial EPS miss, the company’s revenue exceeded forecasts, reaching $11.17 million against an anticipated $9.74 million. Following the earnings announcement, Nektar’s stock experienced a 3.12% decline, closing at $21.75, with further premarket activity indicating a slight decrease [3].

Technical indicators have also raised concerns about the stock's performance. As of 08/13/2025 at 13:15, Nektar Therapeutics' 15-minute chart has reached an overbought level as indicated by the RSI, and a death cross in the KDJ has been triggered. These signals suggest that the stock price has risen too quickly and is no longer supported by fundamentals, leading to a shift in momentum towards the downside and a potential decrease in value [3].

The company’s cash and investments totaled over $1 billion at the end of Q2. Nektar is advancing its lead program, RespEG, in clinical trials and plans to initiate Phase III studies in 2026 [3]. The company projects to end 2025 with $180-$185 million in cash, ensuring a cash runway into 2027. Upcoming data presentations are planned for December 2025 and Q1 2026, which could influence future market positioning and investor sentiment [3].

Executives highlighted the company’s innovative approach, emphasizing the potential impact of Nektar’s clinical advancements. However, significant earnings miss may affect investor confidence, and high R&D expenses could impact short-term profitability. Competitive pressures in the biopharmaceutical sector and regulatory challenges in advancing clinical trials also pose risks [3].

References:
[1] https://www.marketscreener.com/news/nektar-therapeutics-q2-revenue-drops-52-ce7c5edcd98cf12c
[2] https://seekingalpha.com/news/4481799-nektar-therapeutics-non-gaap-eps-of-2_78-beats-by-5_90-revenue-of-11_17m-beats-by-1_75m
[3] https://www.ainvest.com/news/nektar-therapeutics-15min-chart-shows-macd-death-cross-kdj-death-cross-signals-2508/
[4] https://ca.investing.com/news/transcripts/earnings-call-transcript-nektar-therapeutics-reports-q2-2025-earnings-miss-93CH-4146980